ArticleBMC anesthesiology2025
A retrospective cohort of smartpilot view-assisted effect-site TCI anaesthesia in primary total hip and knee arthroplasty.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary total hip arthroplasty and total knee arthroplasty are common surgical procedures that require effective perioperative care to ensure early mobilisation, reduced complications, and shortened hospital stay. Effect-site target-controlled infusion (TCI) combined with SmartPilot View (SPV) is a novel approach to total intravenous anaesthesia that may improve anaesthetic precision and reduce postoperative side effects. However, it has not been thoroughly evaluated in joint arthroplasty. The aim of this study was to evaluate the early anaesthetic outcomes in hip and knee arthroplasty patients following the implementation of effect-site TCI and SPV.
methodsWe conducted a retrospective cohort study including 2316 procedures (2210 patients) at Örebro University Hospital, Lindesberg, Sweden, between 2018 and 2023. Two groups were compared: pre-implementation (2018-2019, n = 1258) using plasma-targeted TCI without SPV, and post-implementation (2022-2023, n = 1058) using effect-site TCI with SPV. Patients from 2020 to 2021 were excluded due to the COVID-19 pandemic and the overlap of methods during implementation. Data were extracted from the Swedish Perioperative Register. The primary outcome was the incidence of postoperative nausea and vomiting (PONV). Secondary outcomes included length of stay in the post-anaesthesia care unit (phase II), postoperative pain, and surgical duration.
resultsPONV incidence decreased significantly from 8.4% to 3.0% after implementation (p < 0.001; adjusted OR: 0.36, 95% CI: 0.23-0.55). Median post-anaesthesia care unit stay decreased by 70 min (95% CI: 61-78 min; p < 0.001). Postoperative pain scores were slightly lower in the post-implementation group (median numeric rating scale 7 vs. 5; p < 0.001). Surgical duration increased marginally (84 vs. 87 min; p = 0.003).
conclusionsImplementation of effect-site TCI and SPV in hip and knee arthroplasty was associated with significantly reduced PONV and shorter post-anaesthesia care unit stay, suggesting improved early postoperative recovery. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.